RxDoctor Payments Data

Wendy Waguespack

Optometrist · Baton Rouge, LANPI 1447319058

Payments from drug & device makers

$4,831in general payments, 2019–2025

Across 143 payments — averaging $33.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Alcon$845
  • AbbVie$549
  • Coopervision Inc.$237
  • Sun Pharmaceutical Industries Inc.$210
  • Genentech USA, Inc.$196
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$1924%
  • Food & beverage$4,60295%
  • Gifts$190%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,831 in reported general payments places this provider in the 85th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$54,875
Medicare patients
315
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$30,842
Cyclosporine17$10,093
LumiganBimatoprost24$10,010
VyzultaLatanoprostene Bunod12$5,041
Travoprost13$2,780
Latanoprost139$2,074
Timolol Maleate52$1,292
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$1,218
Fluorometholone11$909
ErythromycinErythromycin Base26$328
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$306
Brimonidine Tartrate31$236
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$549$40,85259 claims
Bausch & Lomb Americas Inc.Vyzulta$152$5,04112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →